Stocks in play: BioVaxys Technology Corp.
Announced today that it has entered into a major sponsored research collaboration with The Ohio State University to further develop BioVaxys' haptenized viral antigen platform to create a broadly reactive pan-sarbecovirus vaccine. This is the second research collaboration in the SARS-CoV-2 field between BioVaxys, a clinical-stage immunotherapy company developing novel approaches to harness T cells to treat cancer and to detect and prevent emerging infectious diseases; and Ohio State, a leading global academic research institute in the fight against SARS-CoV-2. Ohio State's Wexner Medical Center serves as a site for SARS-CoV-2 multicenter clinical trials. BioVaxys Technology Corp. shares C.BIOV are trading up 0.02 cents at $0.26.
Read:
Oncology Drug Developers Looking at Significant Projected Growth Through 2030
Plant-Based Meats Continue to Sprout Growing Revenues on Year-Over-Year Basis
No Apparent Need to Panic Over Omicron as Vaccine Developers Are on the Case
Plant-Based Meats Market Projected to Hit $162 Billion by 2030, as New Products Launch
Innovations in Plant-Based Protein Products Supplying the Food Industry’s Strongest Trends